# Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants

> **NCT02076373** · PHASE3 · UNKNOWN · sponsor: **University of Zurich** · enrollment: 120 (actual)

## Conditions studied

- Intraventricular Hemorrhage of Prematurity

## Interventions

- **DRUG:** recombinant human Erythropoietin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02076373
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-03
- **Primary completion:** 2023-12
- **Final completion:** 2024-03
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2018-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02076373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02076373, "Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02076373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*